Management Team

Pamela Carroll, Ph.D. joined Genocea in 2016 to lead immuno-oncology efforts.  She brings expertise in cancer biology and immuno-oncology to the development and strategic direction of Genocea’s oncology programs. Her previous positions include vice president of oncology discovery at Roche Pharma Research and Early Development, vice president of Janssen oncology at Johnson and Johnson Innovation, and founding Head of Research at the Belfer Institute for Applied Cancer Science at Dana Farber Cancer Institute.  Dr. Carroll developed her drug discovery experience at Bristol-Myers Squibb in applied genomics and Merck Research Laboratories in oncology. Dr. Carroll earned her B.A. in biology at St. Michael’s College in Vermont, a doctorate in cellular biology at Stony Brook University, and a post-doctorate fellowship at Stanford University.

William Clark has served as our President and Chief Executive Officer since February 2011. Previously he served as our Chief Business Officer from August 2010 to February 2011. Mr. Clark has served on our board of directors since February 2011. Prior to joining our Company, he served as Chief Business Officer at Vanda Pharmaceuticals, Inc. ("Vanda"), a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company’s strategic and business development activities, and played a central role in raising more than $220 million in multiple public and private financings. Prior to Vanda, Mr. Clark was a principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline). Mr. Clark holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Jessica Baker Flechtner, Ph.D. joined Genocea in 2007, soon after the company was founded, and currently serves as the Chief Scientific Officer. Dr. Flechtner is a pioneer in the development of novel vaccines directed toward T cell immunity, and has more than 20 years of experience in immunology, infectious disease, cancer, and vaccine development.  She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against infectious diseases and other indications. Prior to joining Genocea, Dr. Flechtner developed vaccines and immunotherapies for cancer, infectious disease, autoimmunity and allergy in several companies including Mojave Therapeutics and Antigenics Inc. (now Agenus). She is an inventor on ten pending and four issued patents and has multiple peer-reviewed scientific publications. Dr. Flechtner performed her post-doctoral work at the Dana Farber Cancer Institute and Harvard Medical School. She holds a Ph.D. in Cellular Immunology and a B.S. in Animal Science from Cornell University, and is a member of the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, and American Society for Microbiology.

Prior to joining Genocea, Eric was vice president of corporate and business development, program management and commercial operations at Idenix Pharmaceuticals, Inc. before its acquisition by Merck in August 2014. Eric also held roles in investor relations and corporate communications whilst at Idenix. Prior to Idenix, Eric spent four years at Biogen Idec in investor relations and business development roles and spent six years on Wall Street as an equity research analyst at J.P. Morgan, Schwab Soundview Capital Markets and Bear Stearns. Before starting on Wall Street in 2001, he was a post-doctoral research scientist in the Department of Immunobiology at Guy's Hospital in London, studying T cell development. He has authored several book chapters and peer-reviewed papers, including in Cell,Immunity, and Genes & Development. He holds a Ph.D. in Immunobiology from Yale University and a B.S. in Biology from Trinity University.

Prior to joining Genocea, Jonathan was Senior Vice President of Finance for Shire plc (NASDAQ: SHPG). During his time at Shire, Jonathan held a number of senior roles in Finance and Strategic Planning and Portfolio Management, including as leader of the finance teams supporting Shire’s Global Business Development, R&D and Technical Operations activities and divisional CFO and head of Strategic Planning and Portfolio Management of Shire HGT, its Rare Disease division. Jonathan began his career in the UK in investment banking with UBS Warburg and ING Barings and also worked as an investment manager for Avanti Capital Plc, a UK private equity investment firm. Jonathan has a MBA from London Business School and a BSc in Biological Sciences from Durham University in the UK.